Shopping Cart
Remove All
Your shopping cart is currently empty
HIF-1α-IN-8
Copy Product Info
😃Good
Catalog No. T212496
HIF-1α-IN-8 is an orally active inhibitor of HIF-1α with an IC50 of 2.02 μM. It effectively suppresses the expression of inflammatory factors such as IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells, and inhibits the HIF-1α/IKKα/NF-κB signaling pathway. Additionally, it decreases the expression of proteins related to blood-brain barrier permeability. In a high-altitude cerebral edema (HACE) mouse model, HIF-1α-IN-8 lowers brain water content and oxidative stress levels. This compound is suitable for researching high-altitude cerebral edema (HACE).
HIF-1α-IN-8
HIF-1α-IN-8
Copy Product Info😃Good
Catalog No. T212496
HIF-1α-IN-8 is an orally active inhibitor of HIF-1α with an IC50 of 2.02 μM. It effectively suppresses the expression of inflammatory factors such as IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells, and inhibits the HIF-1α/IKKα/NF-κB signaling pathway. Additionally, it decreases the expression of proteins related to blood-brain barrier permeability. In a high-altitude cerebral edema (HACE) mouse model, HIF-1α-IN-8 lowers brain water content and oxidative stress levels. This compound is suitable for researching high-altitude cerebral edema (HACE).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | HIF-1α-IN-8 is an orally active inhibitor of HIF-1α with an IC50 of 2.02 μM. It effectively suppresses the expression of inflammatory factors such as IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells, and inhibits the HIF-1α/IKKα/NF-κB signaling pathway. Additionally, it decreases the expression of proteins related to blood-brain barrier permeability. In a high-altitude cerebral edema (HACE) mouse model, HIF-1α-IN-8 lowers brain water content and oxidative stress levels. This compound is suitable for researching high-altitude cerebral edema (HACE). |
| Targets&IC50 | HIF1α:2.02 μM |
| In vitro | HIF-1α-IN-8 (Compound N41) at a concentration of 20 μM for 48 hours inhibits the secretion of inflammatory factors IL-6 and NO in C8-D1A cells. When used at concentrations ranging from 5-50 μM for 12 hours, it reduces hypoxia-induced ROS production and apoptosis in these cells. Additionally, at 5-20 μM for 24 hours, HIF-1α-IN-8 suppresses the expression of key proteins in the HIF-1α/IKKα/NF-κB signaling pathway (HIF-1α, IKKα, p65, IκBα) and decreases the expression of blood-brain barrier permeability-related proteins MMP-9 and AQP-4 in C8-D1A cells. |
| In vivo | HIF-1α-IN-8 (Compound N41), administered orally at doses of 25-100 mg/kg once daily for three days, reduces brain water content and oxidative stress levels in mice models of high-altitude cerebral edema (HACE). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy HIF-1α-IN-8 | purchase HIF-1α-IN-8 | HIF-1α-IN-8 cost | order HIF-1α-IN-8 | HIF-1α-IN-8 in vivo | HIF-1α-IN-8 in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.